NCT05317078View on ClinicalTrials.gov

A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications

PHASE1TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

December 19, 2023

Study Completion Date

April 1, 2024

Conditions
Non-squamous Non-small Cell Lung CancerEpithelial Ovarian CancerClaudin 6-positive Advanced/Metastatic Malignant Solid Tumors
Interventions
DRUG

AMG 794

Short-term intravenous (IV) infusion.

Trial Locations (8)

3010

Inselspital Bern, Bern

3144

Cabrini Hospital, Malvern

3168

Monash Medical Centre, Clayton

5042

Southern Oncology Clinical Research Unit, Bedford Park

23219

Virginia Commonwealth University, Richmond

91010

City of Hope National Medical Center, Duarte

92868

University of California Irvine, Orange

90095-1678

University of California Los Angeles, Los Angeles

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT05317078 - A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications | Biotech Hunter | Biotech Hunter